Phoebe J. Ho

Sydney, NSW, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.

Journal: Lancet (London, England)

Published: April 29, 2026

Updated guidelines in the treatment of myeloma bone disease in 2025: consensus statement by the Medical and Scientific Advisory Group of Australia (MSAG) to Myeloma Australia.

Updated guidelines in the treatment of myeloma bone disease in 2025: consensus statement by the Medical and Scientific Advisory Group of Australia (MSAG) to Myeloma Australia.

Journal: Expert review of hematology

Published: October 13, 2025

No benefit from daratumumab, bortezomib and dexamethasone (D-Vd) in real-world patients with functional high-risk multiple myeloma: A report from the Myeloma and Related Diseases Registry.

No benefit from daratumumab, bortezomib and dexamethasone (D-Vd) in real-world patients with functional high-risk multiple myeloma: A report from the Myeloma and Related Diseases Registry.

Journal: British journal of haematology

Published: August 11, 2025

Real-world Australian experience with tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma-importance of pre-CAR-T optimization.

Real-world Australian experience with tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma-importance of pre-CAR-T optimization.

Journal: Frontiers in oncology

Published: May 23, 2025

Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial.

Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial.

Journal: The Lancet. Oncology

Published: May 14, 2025

Presence of 1q21 Gain and Amplification May be Associated With Poorer Outcomes in Daratumumab-treated Multiple Myeloma Patients.

Presence of 1q21 Gain and Amplification May be Associated With Poorer Outcomes in Daratumumab-treated Multiple Myeloma Patients.

Journal: Clinical lymphoma, myeloma & leukemia

Published: July 05, 2024

Chimeric antigen receptor T-cell therapy.

Chimeric antigen receptor T-cell therapy.

Journal: Australian prescriber

Published: December 06, 2023

Paternal early life stress exerts intergenerational effects on male C57Bl/6J offspring risk-taking behaviors and predator scent-induced c-Fos expression.

Paternal early life stress exerts intergenerational effects on male C57Bl/6J offspring risk-taking behaviors and predator scent-induced c-Fos expression.

Journal: Neuronal signaling

Published: November 20, 2022

Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

Journal: Internal medicine journal

Published: June 10, 2022

Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignancies.

Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignancies.

Journal: Internal medicine journal

Published: May 24, 2022

Australia and New Zealand Transplant and Cellular Therapies (ANZTCT) position statement: COVID-19 management in patients with haemopoietic stem cell transplant and chimeric antigen receptor T cell.

Australia and New Zealand Transplant and Cellular Therapies (ANZTCT) position statement: COVID-19 management in patients with haemopoietic stem cell transplant and chimeric antigen receptor T cell.

Journal: Internal medicine journal

Published: May 17, 2022

Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction.

Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction.

Journal: European journal of haematology

Published: May 04, 2021

Showing 1-12 of 16

Last Updated: 09/26/2026